Breaking News Instant updates and real-time market news.

ULTA

Ulta Beauty

$234.90

1.85 (0.79%)

, AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

09:25
08/20/18
08/20
09:25
08/20/18
09:25

Ulta Beauty Q2 may outperform based on competitor trends, says Loop Capital

Loop Capital analyst Anthony Chukumba is keeping his Hold rating and $250 price target on Ulta Beauty (ULTA) ahead of its Q2 earnings next week, but notes that there may be some upside to his expectations based on the positive recent competitor commentary. The analyst expects investors to focus on the comparable and mass cosmetics sales growth, along with the company's operating margins and future earnings guidance, particularly in light of the slowing sequential comps growth trends over the past 6 quarters and concerns about the Amazon (AMZN) inroads in the prestige cosmetics market.

ULTA

Ulta Beauty

$234.90

1.85 (0.79%)

AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

  • 30

    Aug

  • 13

    Sep

ULTA Ulta Beauty
$234.90

1.85 (0.79%)

07/26/18
07/26/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. PIPER CUTS 3D SYSTEMS TO UNDERWEIGHT: Piper Jaffray analyst Troy Jensen downgraded 3D Systems (DDD) to Underweight from Neutral with a $10 price target. He believes competition for the company's main product lines is intensifying. The analyst also thinks 3D will need to increase spending on direct sales, customer support and consulting, meaning "meaningful profitability" will likely be more challenged than revenue growth throughout 2018. He views the stock as overvalued. While Jensen continues to believe the overall 3D printing industry is "growing rapidly," he remains cautious on shares of 3D Systems and Stratasys (SSYS). He reiterated a Neutral rating on the latter. OPCO CUTS E.L.F. TO PERFORM: Oppenheimer analyst Rupesh Parikh downgraded e.l.f. Beauty (ELF) to Perform from Outperform saying the bull case is more uncertain from here. The analyst does not have a price target for the shares. Recent developments, including "still challenging trends" in the mass category and increased tariff uncertainty, bring greater risk to consensus forecasts, Parikh tells investors in a research note. He is harder-pressed to see the case for share outperformance. Ulta Beauty (ULTA) and Estee Lauder (EL) remain Parikh's top picks in beauty. FACEBOOK GETS MULTIPLE DOWNGRADES AFTER Q2 EARNINGS: Nomura Instinet analyst Mark Kelley downgraded Facebook (FB) to Neutral from Buy after the company delivered "underwhelming" Q2 results and guided for revenue growth deceleration through the end of the year. The revenue guidance paired with the expectation for mid-30% operating margins in the medium term or possibly longer means consensus numbers will be cut "drastically," he said. He lowered his price target on Facebook shares to $183 from $228. Facebook was also downgraded to Neutral from Buy by UBS analyst Eric Sheridan, who also lowered his price target for the shares to $180 from $212, and to Outperform from Strong Buy at Raymond James. Facebook shares are down over 19% in late morning trading. PIPER SAYS BIOGEN SELLOFF A BUYING OPPORTUNITY: Biogen (BIIB) shares "will recover and continue to work" into aducanumab's full Phase 3 data in 2020, Piper Jaffray analyst Christopher Raymond told investors. With the stock having run up into these data, the analyst said he understood the "sell-the-news" phenomenon. He believes, however, that the fundamental concerns he's heard from investors "don't seem to hold water." The analyst said to buy Biogen shares on the selloff. He kept an Overweight rating on the name with a $400 price target.
07/30/18
JEFF
07/30/18
NO CHANGE
Target $285
JEFF
Buy
Ulta Beauty removed from Franchise Pick List at Jefferies
Jefferies analyst Stephanie Wissink removed Ulta Beauty from her firm's Franchise Pick List but keeps a Buy rating on the shares with a $285 price target. The analyst is starting to see signs that the "hyper-consumption cycle" in beauty has peaked and the rate of growth is moderating. Wissink, however, remains confident in Ulta's ability to capture market share.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/20/18
WELS
08/20/18
NO CHANGE
Target $278
WELS
Outperform
Ulta Beauty price target lowered to $278 from $297 at Wells Fargo
Wells Fargo analyst Ike Boruchow lowered his price target for Ulta Beauty to $278 from $297 as he believes Q2 performance may not have been as robust as originally expected, as his checks indicate a continuation of soft beauty trends and slowdown in traffic to end the quarter. The analyst reiterates an Outperform rating on the shares.
AMZN Amazon.com
$1,881.94

-5.56 (-0.29%)

08/13/18
PIPR
08/13/18
NO CHANGE
Target $2100
PIPR
Overweight
Piper believes Amazon's ad business should be valued at $150B-$190B
Amazon.com's advertising business "has been quietly growing into a massive driver of current and future profitability," Piper Jaffray analyst Michael Olson tells investors in a research note. The analyst estimates that in 2018, Amazon advertising revenue will be around $8B, potentially contributing greater than $3B to operating profit. By 2020, he expects Amazon ad revenue of $16B and by 2021, he believes it is highly likely that profits contributed from advertising will exceed those from Amazon Web Services. Applying an advertising comp multiple of 16 times to estimated 2020 Amazon advertising operating income suggests an ad business that should be valued at $150B-$190B, Olson contends. As such, he believes investors "should be focused on Amazon advertising now." The analyst reiterates an Overweight rating on Amazon shares with a $2,100 price target. The stock closed Friday down $12.22 to $1,886.30.
08/13/18
08/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN SACHS CUTS ALNYLAM TO BUY: Goldman Sachs analyst Terence Flynn downgraded Alnylam (ALNY) to Buy from Conviction Buy. The analyst also lowered his price target for the shares to $155 from $193. Flynn said the lack of cardio data in the approved U.S. label for Onpattro is disappointing and could represent a disadvantage versus Pfizer's (PFE) competitor drug Tafamadis. Piper Jaffray analyst Edward Tenthoff recommended buying shares of Alnylam Pharmaceuticals on weakness following the approval of Onpattro. Morgan Stanley analyst David Lebowitz lowered his price target to $93, Nomura Instinet analyst Christopher Marai lowered his price target to $73, and Stifel analyst Paul Matteis maintained a Buy rating but cut his price target to $123 from $125 and slightly lowered his revenue ramp for the drug based on modestly reduced share in mixed-phenotype haTTR patients and lower share in cardiac-only haTTR patients. B. Riley FBR analyst Madhu Kumar raised his price target to $230. RUBIUS THERAPEUTICS INITIATED AT MULTIPLE FIRMS: Rubius Therapeutics (RUBY) was initiated with an Outperform at Leerink, an Overweight at JPMorgan and Morgan Stanley, as well as a Buy at Jefferies. PIPER JAFFRAY SAYS AMAZON AD BUSINESS GROWING INTO PROFIT DRIVER: Amazon's (AMZN) advertising business "has been quietly growing into a massive driver of current and future profitability," Piper Jaffray analyst Michael Olson told investors in a research note. Applying an advertising comp multiple of 16 times to estimated 2020 Amazon advertising operating income suggests an ad business that should be valued at $150B-$190B, Olson contended. IMPERIAL CAPITAL CUTS NETFLIX PRICE TARGET TO $494: Imperial Capital analyst David Miller lowered his price target for Netflix (NFLX) to $494 after he slightly reduced his global subscriber estimates. The analyst said that in the "interest of being conservative," he decreased his fiscal 2018 global subscriber estimate to 141.2M from 141.4M and fiscal 2019 global subscriber estimate to 164.4M from 166.3M. DISH DOWNGRADED TO SELL AT MOFFETTNATHANSON: MoffettNathanson analyst Craig Moffett downgraded Dish (DISH) to Sell from Neutral with a price target of $29 and noted that while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment -- which holds "all" of the company's equity value -- is worse.
08/17/18
ARGS
08/17/18
NO CHANGE
Target $112
ARGS
Buy
Walmart price target raised to $112 from $100 at Argus
Argus analyst Chris Graja raised his price target on Walmart (WMT) to $112, citing the company's decade-best Q2 comps growth and a positive update on its e-commerce business, which grew by 40% in Q1. Graja also notes that online grocery sales were strong, as the department delivered its best comps growth in 9 years to retain its competitive position against Amazon's (AMZN) Whole Foods unit. The analyst keeps his Buy rating on Walmart and contends that the company is immune to the primary risk of "irrelevance" for retailers, stating that it plays an "important" role in the economy with its buying power and "logistical prowess".
08/20/18
RBCM
08/20/18
NO CHANGE
Target $172
RBCM
Outperform
VMware to deliver 'solid quarterly results', says RBC Capital
RBC Capital analyst Matthew Hedberg kept his Outperform rating and $172 price target on VMware (VMW) ahead of its earnings, saying the recent surveys and his positive meetings with the management during the quarter suggest the company will deliver "solid" results. The analyst maintains that "VMware is well-positioned to capitalize on hybrid-cloud adoption", adding he is also looking for signs of additional growth on its core-compute platform, Dell synergies, and its Amazon (AMZN) AWS partnership.

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.